Ahmet Ozdemir | Medicinal Chemistry | Best Researcher Award

Dr Ahmet Ozdemir | Medicinal Chemistry | Best Researcher Award

Professor Doctorate, Anadolu University ,Turkey.

Ahmet ÖZDEMİR, born on July 24, 1972, in Muğla, Turkey, is a Professor of Pharmaceutical Chemistry at Anadolu University, where he has been a faculty member since 1997. He earned his undergraduate degree in Pharmacy from Anadolu University (1990-1994), followed by an M.Sc. in Pharmaceutical Chemistry (1995-1996) and a Ph.D. in the same field (1996-2004), with research focusing on the synthesis and biological activities of novel compounds. Dr. ÖZDEMİR has held various academic positions at Anadolu University, advancing from Research Assistant to Professor. He has also served in administrative roles, including Associate Director of Anadolu University Yunus Emre Vocational School and Vice Academic Director of the Open Education Faculty’s Department of Health Administration. His research is well-regarded, earning him multiple awards, including the Anadolu University Article Performance Award and the ISIF’21 Silver Medal for his work on targeted novel triazolothiadiazine derivatives for lung cancer treatment.

Profile:

Education

Prof. Dr. Ahmet Özdemir’s educational journey began at Salihli Cumhuriyet Elementary School, where he completed his primary education from 1978 to 1983. He continued his secondary education at Salihli 50. Yıl Secondary School from 1983 to 1986, and then attended Salihli High School from 1986 to 1989, where he completed his high school education. Prof. Dr. Özdemir pursued his undergraduate studies at Anadolu University Faculty of Pharmacy, graduating in 1994. He furthered his education with a Master’s Degree in Pharmaceutical Chemistry at Anadolu University’s Graduate School of Health Sciences from 1995 to 1996, where he completed his thesis. He continued at Anadolu University for his Doctoral Degree in Pharmaceutical Chemistry, which he achieved in 2004. Additionally, he possesses intermediate proficiency in English, which complements his academic background and research expertise.

Academic Titles

Prof. Dr. Ahmet Özdemir’s academic career at Anadolu University’s Faculty of Pharmacy spans several roles and achievements. He began his journey as a Research Assistant in 1997, a position he held until 2004. Following this, he advanced to the role of Research Assistant Doctor, continuing his work at the same institution from 2004 to 2005. Dr. Özdemir was then appointed as a Lecturer from 2005 to 2007, showcasing his growing expertise in the field. His contributions were recognized with a promotion to Assistant Professor Doctor, a role he embraced from 2007 to 2010. His exceptional work led to his promotion to Associate Professor Doctor, a position he held from 2010 to 2015. Since 2015, Prof. Dr. Özdemir has served as Professor Doctor, continuing to make significant contributions to the Faculty of Pharmacy and the broader academic community.

Awards

Prof. Dr. Ahmet Özdemir has received several prestigious awards for his academic and research contributions. In 2014, he was honored with the Anadolu University Article Performance Award. His outstanding achievements continued with the Anadolu University Gold Article Performance Award and the Anadolu University Platinum Article Performance Award in 2015. He maintained a high standard of excellence, receiving the Anadolu University Article Performance Award annually from 2016 to 2018. In 2019, Dr. Özdemir was recognized with the Anadolu University Academic Success Award. His consistent performance earned him the Anadolu University Article Performance Award again in 2020. Notably, in 2021, he was awarded the ISIF’21 Silver Medal for the invention titled “Targeted Novel Triazolothiadiazine Derivatives for the Treatment of Lung Cancer” at the 6th Istanbul International Inventions Fair (ISIF’21). This award was shared with Assoc. Prof. Dr. Belgin Sever, Prof. Dr. Mehlika Dilek Altintop, and Prof. Dr. Gülşen Akalın Çiftçi.

Research Focus

Prof. Dr. Ahmet Özdemir’s research is dedicated to the field of medicinal chemistry, with a keen focus on several key areas. He specializes in the synthesis of bioactive compounds, aiming to develop novel chemical entities with potential therapeutic uses, particularly targeting antifungal and antibacterial applications. His work in pharmaceutical chemistry involves investigating the physicochemical properties of these compounds, which has significant implications for drug design and efficacy. Dr. Özdemir also explores antimicrobial agents, focusing on the synthesis and evaluation of compounds designed to combat bacterial and fungal pathogens. In the realm of drug design and development, he examines structure-activity relationships to create effective and selective pharmaceutical agents. Additionally, his contributions extend to invention and innovation, where he develops novel chemical derivatives, such as triazolothiadiazine derivatives, for potential applications in treating diseases like lung cancer.

Publications

  1. “Design, synthesis and biological evaluation of a new series of imidazothiazole-hydrazone hybrids as dual EGFR and Akt inhibitors for NSCLC therapy”
    • Authors: Altıntop, M.D., Ertorun, İ., Akalın Çiftçi, G., Özdemir, A.
    • Year: 2024
  2. “Design, Synthesis, and In Vivo Evaluation of a New Series of Indole-Chalcone Hybrids as Analgesic and Anti-Inflammatory Agents”
    • Authors: Baramaki, I., Altıntop, M.D., Arslan, R., Hasan, A., Bektaş Türkmen, N.
    • Year: 2024
  3. “Design, Synthesis, and Evaluation of a New Series of 2-Pyrazolines as Potential Antileukemic Agents”
    • Authors: Altıntop, M.D., Cantürk, Z., Özdemir, A.
    • Year: 2023
  4. “Design, Synthesis, and Evaluation of a New Series of Hydrazones as Small-Molecule Akt Inhibitors for NSCLC Therapy”
    • Authors: Erdönmez, B., Altıntop, M.D., Akalın Çiftçi, G., Özdemir, A., Ece, A.
    • Year: 2023
  5. “A new series of hydrazones as small-molecule aldose reductase inhibitors”
    • Authors: Altıntop, M.D., Demir, Y., Türkeş, C., Beydemir, Ş., Özdemir, A.
    • Year: 2023
  6. “A new series of thiazole-hydrazone hybrids for Akt-targeted therapy of non-small cell lung cancer”
    • Authors: Orujova, T., Ece, A., Akalın Çiftçi, G., Özdemir, A., Altıntop, M.D.
    • Year: 2023
  7. “Discovery of Small Molecule COX-1 and Akt Inhibitors as Anti-NSCLC Agents Endowed with Anti-Inflammatory Action”
    • Authors: Altıntop, M.D., Akalın Çiftçi, G., Yılmaz Savaş, N., Alataş, Ö., Özdemir, A.
    • Year: 2023
  8. “Microwave-assisted synthesis of a series of 4,5-dihydro-1H-pyrazoles endowed with selective COX-1 inhibitory potency”
    • Authors: Altıntop, M.D., Temel, H.E., Özdemir, A.
    • Year: 2023
  9. “Design, synthesis and biological evaluation of a new series of arylidene indanones as small molecules for targeted therapy of non-small cell lung carcinoma and prostate cancer”
    • Authors: Altıntop, M.D., Özdemir, A., Temel, H.E., Kaplancıklı, Z.A., Akalın Çiftçi, G.
    • Year: 2022
  10. “A new series of thiosemicarbazone-based anti-inflammatory agents exerting their action through cyclooxygenase inhibition”
    • Authors: Altıntop, M.D., Sever, B., Akalın Çiftçi, G., Alataş, Ö., Özdemir, A.
    • Year: 2022